We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Processa Pharmaceuticals Inc | NASDAQ:PCSA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 4.26% | 2.45 | 2.44 | 2.48 | 2.55 | 2.30 | 2.34 | 127,869 | 01:00:00 |
1. Name and Address of Reporting Person * BESSER JAMES E | 2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [ PCSA ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner _____ Officer (give title below) __X__ Other (specify below) See Remarks |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock, $0.01 par value | 4/6/2021 | S | 31771 | D | $10.91 | 1064300 | I | See footnotes (1)(2) | ||
Common Stock, $0.01 par value | 4/7/2021 | S | 16000 | D | $10.67 | 1048300 | I | See footnotes (1)(2) | ||
Common Stock, $0.01 par value | 4/8/2021 | S | 400000 | D | $10.76 | 648300 | I | See footnotes (1)(2) | ||
Common Stock, $0.01 par value | 405000 | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Remarks: As of as of April 07, 2021, the Reporting Person is no longer subject to the reporting requirements of Section 16 of the Securities Exchange Act of 1934. The original Form 4, filed April 8, 2021, is being amended by this Form 4 amendment solely to correct an administrative error, which mistakenly inverted the ownership codes in Table I, Item 6, showing indirectly held shares as directly held and vice versa. |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
BESSER JAMES E 53 PALMERAS STREET CARIBE PLAZA BUILDING, 6TH FLOOR SAN JUAN, PR 00901 | See Remarks |
Signatures | ||
/s/ James E. Besser | 5/5/2021 | |
**Signature of Reporting Person | Date |
1 Year Processa Pharmaceuticals Chart |
1 Month Processa Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions